Market Overview

Savara to Report First Quarter 2019 Financial Results and Provide Business Update

Share:

Savara
Inc.
(NASDAQ:SVRA), an orphan lung disease company, today announced
that the Company will report first quarter 2019 financial results and
provide a business update on Thursday, May 9, 2019. Savara management
will host a conference call at 4:30 p.m. Eastern Time (ET)/1:30 p.m.
Pacific Time (PT).

Shareholders and other interested parties may access the conference call
by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and
(412) 542-4127 from elsewhere outside the U.S. and request the "Savara
Inc." call. A live webcast of the conference call will be available
online in the Investors section of Savara's website at https://www.savarapharma.com/investors/events-presentations/.

Approximately one hour after the call, a replay of the webcast will be
available on Savara's website for 30 days, and a telephone replay will
be available through May 16, 2019 by dialing (877) 344-7529 from the
U.S., (855) 669-9658 from Canada and (412) 317-0088 from elsewhere
outside the U.S. and entering the replay access code 10130971.

About Savara

Savara is an orphan lung disease company. Savara's pipeline comprises
Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor
(GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar
proteinosis (aPAP), in Phase 2a development for nontuberculous
mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and
CF-affected individuals with chronic NTM lung infection; and AeroVanc, a
Phase 3-stage inhaled vancomycin for treatment of persistent
methicillin-resistant Staphylococcus aureus (MRSA) lung infection
in CF. Savara's strategy involves expanding its pipeline of potentially
best-in-class products through indication expansion, strategic
development partnerships and product acquisitions, with the goal of
becoming a leading company in its field. The most recent acquisition is
aerosolized amikacin/fosfomycin, a Phase 2-ready, proprietary
combination antibiotic, which has demonstrated potent and broad-spectrum
antibacterial activity against highly drug resistant pathogens. Savara's
management team has significant experience in orphan drug development
and pulmonary medicine, identifying unmet needs, developing and
acquiring new product candidates, and effectively advancing them to
approvals and commercialization. More information can be found at www.savarapharma.com.
(Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)

View Comments and Join the Discussion!
 
Lightning Fast
Market News Service
$199 Free 14 Day Trial